The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

“…The company suggests a cut-off point of 85, based on a study of PE cases and controls that included women with singleton pregnancies and normal pregnancy outcome. 56 …”

New Developments in the Pathogenesis of Preeclampsia

“…This simple, quantitative, rapid test outperformed the standard battery of clinical diagnostic measures including blood pressure, proteinuria, uric acid, and other laboratory assays 57 . Importantly, sFlt1 and/or PlGF levels at presentation were strongly associated with the remaining duration of pregnancy 53,[57][58][59][60] . We also recently evaluated the role of sEng measurements and found that it has comparable performance to sFlt1/PlGF ratio 61 .…”

“…A number of recent studies have suggested that circulating angiogenic factors in plasma or urine can be used to differentiate preeclampsia from other diseases that mimic preeclampsia such as chronic hypertension, gestational hypertension, lupus nephritis and gestational thrombocytopenia [47][48][49][50][51][52][53][54][55][56] . To demonstrate clinical utility, we prospectively studied the role of angiogenic biomarkers in the prediction of preeclampsia related adverse outcomes among women evaluated at our institution for suspected preeclampsia.…”

Obstetric Nephrology

“…These include women with underlying proteinuric renal disease, collagen vascular disorders with renal manifestations (e.g., lupus nephritis), moderate CKD, renal allografts, another hypertensive disorder, or women who may have an alternative cause of thrombocytopenia. The sFlt/PlGF ratio distinguishes preeclampsia (or SIPE) from either GH or CHTN, especially before 34 weeks of GA (29). Very high ratios before 34 weeks of GA in women with suspected preeclampsia predict the occurrence of adverse maternal or perinatal outcomes within a 2-week horizon and are associated with imminent delivery, whether for maternal or fetal indications (29,30).…”

“…The sFlt/PlGF ratio distinguishes preeclampsia (or SIPE) from either GH or CHTN, especially before 34 weeks of GA (29). Very high ratios before 34 weeks of GA in women with suspected preeclampsia predict the occurrence of adverse maternal or perinatal outcomes within a 2-week horizon and are associated with imminent delivery, whether for maternal or fetal indications (29,30). In this sense, one might imagine that such risk stratification could aid in more efficient clinical resource allocation among hypertensive gravidas, although it seems unlikely in the absence of compelling, well designed, and adequately powered prospective trials, that discrimination would be adequate to allow some women to be discharged, whereas others remain in hospital, based on these tests alone.…”